Cogentis Therapeutics is an early stage biotechnology company with a mission to develop and commercialize an innovative disease-modifying therapeutic for dementias such as frontotemporal dementia (FTD) and Alzheimer’s disease (AD) to improve patients’ quality of life and reduce the burden of disease on their families, providers, and the overall healthcare system. Our immediate goal is to develop a peptide-based compound, CT-526, for FTD.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 3717 Boston Street, Baltimore,maryland 21224,united States
- Phone
- 443.842.6856
- we****@****stx.com
- Industry
- Biotechnology
- Website
- cogentistherapeutics.com
- Keywords
- neurodegeneration, neuropeptide, frontotemporal dementia, Alzheimer's disease, progressive supranuclear palsy.
- HQ
- Baltimore, Maryland
Cogentis Therapeutics, Inc. Questions
Cogentis Therapeutics, Inc.'s helpline number is 443.842.6856
Cogentis Therapeutics, Inc.'s website is cogentistherapeutics.com
Cogentis Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/cogentis-therapeutics
Cogentis Therapeutics, Inc. has
6 employees.
View email and phone details for 6
employees at Cogentis Therapeutics, Inc..
Cogentis Therapeutics, Inc.'s industry is
Biotechnology
Cogentis Therapeutics, Inc.'s top competitors are
Macrogenics, Inc.,
Deka Biosciences, Inc,
Aavogen,
Elixirgen Therapeutics, Inc.,
Kaigene, Inc,
Cogentis Srl,
Cogentis,
Pathovax Llc,
Cognition Therapeutics, Inc.,
Riverwalk Therapeutics, Inc..
Cogentis Therapeutics, Inc.'s support email address is we-care@cogentistx.com
Cogentis Therapeutics, Inc.'s categories are Biotechnology
Cogentis Therapeutics, Inc.'s founding year is 2015
